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Abstract 
Since the severe acute respiratory syndrome (SARS) outbreak in 2003, human coronaviruses 
(hCoVs) have been identified as causative agents of severe acute respiratory tract infections. 
Two more hCoV outbreaks have since occurred, the most recent being SARS-CoV-2, the 
causative agent of coronavirus disease 2019 (COVID-19). The clinical presentation of SARS 
and MERS is remarkably similar to COVID-19, with hyperinflammation causing a severe form 
of the disease in some patients. Previous studies show that the expression of the SARS-CoV E 
protein is associated with the hyperinflammatory response that could culminate in acute 
respiratory distress syndrome (ARDS), a potentially fatal complication. This immune-mediated 
damage is largely caused by a cytokine storm, which is induced by significantly elevated levels 
of inflammatory cytokines interleukin (IL)-1 and IL-6, which are partly mediated by the 
expression of the SARS-CoV E protein. The interaction between the SARS-CoV E protein and 
the host protein, syntenin, as well as the viroporin function of SARS-CoV E, are linked to this 
cytokine dysregulation. This review aims to compare the clinical presentation of virulent 
hCoVs with a specific focus on the cause of the immunopathology. The review also proposes 
that inhibition of IL-1 and IL-6 in severe cases can improve patient outcome. 
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Introduction 
Coronaviruses (CoVs) (order Nidovirales) all have positive sense, single-stranded RNA 
genomes that range in size between 26 and 32 kilobases (kb) [1, 2]. While they predominantly 
infect animals, some have, in decades past, been able to cross the species barrier and infect 
humans. Seven human CoVs (hCoVs) have been identified, of which four – hCoVs 229E, 
NL63, OC43, and HKU1 – are distributed globally, circulating continuously within the human 
population, causing mild-to-moderate, self-limiting infections [3]. Conversely, the other three 
hCoVs, – severe acute respiratory syndrome (SARS)-CoV, Middle East respiratory syndrome 
(MERS)-CoV, and SARS-CoV-2 – are more virulent and have caused deadly outbreaks during 
the past two decades [4-6].  
SARS-CoV caused the first deadly hCoV outbreak in 2003, which was successfully contained 
in little over six months [7]. The SARS-CoV outbreak resulted in 8096 laboratory-confirmed 
infections worldwide with 774 deaths, a case-fatality rate of 9.6% [8]. In 2012, the MERS-CoV 
was identified as the causative agent of MERS in Saudi-Arabia [9]. The MERS-CoV outbreak 
of 2012 saw a case-fatality rate of 34.4% from 2499 laboratory-confirmed cases and 861 
associated deaths as of December 2019 [10]. Then, at the end of 2019, SARS-CoV-2 (formerly 
known as 2019-nCoV) was reported to be responsible for another outbreak of a SARS-like 
disease in Wuhan, China [11-13]. As of 20 May 2020, 4 789 205 confirmed cases of SARS-
CoV-2 infections with at least 318 789 deaths were reported worldwide [14].  
Undoubtedly, SARS-CoV-2 has an infective profile vastly different from that of the SARS-
CoV and MERS-CoV. This is especially evident by the incredibly rapid spread, but much lower 
case-fatality rate of SARS-CoV-2. The disease associated with the virus was named 
coronavirus disease 2019 (COVID-19) and is the first hCoV outbreak to be declared a 
pandemic [15, 16]. This review compares the clinical presentation of the virulent hCoVs, 
SARS-CoV and MERS-CoV, to the symptoms reported in COVID-19 patients to date. 
Evidence is also presented to call attention to the hCoV protein responsible for the 
immunopathology often seen in severe cases of pathogenic hCoV infections, and how this 
protein drives the hyperinflammatory response behind this immunopathology. The major 
inflammatory cytokines involved in this response are highlighted and linked to the 
inflammatory cytokines reported in COVID-19 patients. Interim potential treatment options 
that can minimise disease severity, alleviate the burden of disease, and improve patient 
outcome are proposed while antiviral and vaccine research is still ongoing. 
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SARS-CoV and MERS-CoV: a historical perspective 
SARS- and MERS-CoV cause more severe disease, even in immunocompetent, healthy 
individuals [17]. Patients infected with SARS-CoV present with symptoms resembling atypical 
pneumonia, exhibiting fever, chills, headache, malaise, myalgia, and dry cough [18-20]. Those 
infected with MERS-CoV report similar non-specific symptoms, but demonstrate a much 
higher case-fatality rate, particularly for elderly persons and those with underlying medical 
conditions [21-23]. In some cases, a small proportion of both SARS and MERS patients 
develop gastrointestinal symptoms (GIT) such as nausea, vomiting, or diarrhoea.  
The incubation period for SARS is typically between two and seven days, but can be up to 
fourteen days, while for MERS it ranges from two to fourteen days with a median of 
approximately five days [24, 25]. Unlike the four common hCoVs, the severity of SARS and 
MERS could likely be attributed to their lack of continuous circulation in the human population. 
The latter hCoVs had not adapted well to humans as hosts and only managed to cause outbreaks 
after crossing the species barrier, gaining access to the human population from their animal 
reservoir through an intermediate host [26-28]. 
Patients infected with SARS-CoV and MERS-CoV are at risk of developing acute respiratory 
distress syndrome (ARDS), a common complication for both viruses. SARS-CoV and MERS-
CoV infections have been linked to diffuse alveolar damage (DAD) and are characterised by 
increased capillary permeability in the lungs, fluid accumulation in the alveoli, coupled with 
impaired fluid removal mechanisms that culminate in pulmonary oedema, inefficient gas 
exchange, and death [29-31]. The incidence of ARDS can be up to 25% in SARS patients, with 
an associated mortality rate of approximately 50% in these patients [29, 30]. In MERS patients, 
the incidence of ARDS was less commonly reported, but could develop in 12-20% of patients 
[22, 32]. In comparison, some studies have reported that 17-41% of COVID-19 patients had 
developed ARDS [33, 34]. 
Pro-inflammatory cytokines drive the inflammatory response behind ARDS and are a major 
contributor to the progression thereof [35]. Several studies report elevated levels of pro-
inflammatory cytokines and chemokines (i.e. interleukin (IL)-1, IL-6, IL-8, IL-12, tumour 
necrosis factor  (TNF-), interferon  (IFN-), CXCL9, CXCL10, CCL2, CCL3, CCL5, 
granulocyte-macrophage colony-stimulating factor (GM-CSF), and interferon-γ inducible 
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protein 10 kD (IP-10)) associated with the development of ARDS in both SARS and MERS 
patients [26, 35, 36].  
 
SARS-CoV-2 
A lack of epidemiological and serological information on SARS-CoV-2 currently limits our 
understanding of COVID-19, but patient data from hospitals in Wuhan have provided some 
insight into its clinical presentation. Patients exhibit fever, dry cough, myalgia, and shortness 
of breath with ARDS as a common complication [33, 37, 38]. A small number of people also 
developed GIT symptoms [39, 40]. Similar to SARS and MERS, the elderly and those with 
underlying, chronic medical conditions, such as diabetes, hypertension, cardiovascular disease, 
and chronic obstructive pulmonary disease (COPD) are more prone to serious outcomes; 
complications associated with ARDS and a cytokine storm, often succumbing to the infection 
[37, 39]. Interestingly, patients who developed ARDS and are admitted to the ICU also have 
higher levels of inflammatory cytokines, consistent with severe SARS and MERS infections 
[33, 35, 37, 41, 42].  
Like SARS and MERS, these cytokines typically include IL-1, IL-2, IL-4, IL-7, IL-10, IL-12, 
IL-13, IL-17, granulocyte colony-stimulating factor (GCSF), macrophage colony-stimulating 
factor (MCSF), IP-10, monocyte chemoattractant protein-1 (MCP-1), macrophage 
inflammatory protein 1-α (MIP-1α), hepatocyte growth factor (HGF), IFN-γ, and TNF-α and, 
when released collectively in hyperinflammatory conditions, are referred to as a cytokine storm 
[37, 43-45]. Already, several reports have remarked on the clinical similarity between COVID-
19, MERS and SARS with respect to its clinical presentation [37, 38, 46-56].  
The exact cause of this immune-mediated damage, however, remains largely unknown. 
However, the answer may lie in the mechanics of the viral life cycle and the components that 
orchestrate it. After all, some viral proteins, especially those involved in pathogenesis, 
adversely affect the host cell and can be directly implicated in the development of symptoms 
and, ultimately, the clinical presentation [57]. 
Viral proteins: at the expense of the host 
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Viruses by their very nature rely entirely on their host cells for replication, propagation, and, 
ultimately, survival which is achieved by subverting the protein-protein interaction (PPI) 
networks of their host cells [58-60]. This subversion requires that viruses encode proteins with 
the necessary motifs to exploit the network of proteins that govern certain host cell processes 
of benefit to them [61, 62]. The specific motifs, or stretches of peptide sequences, exploited by 
viruses have received some attention, but, for the most part, have been quite understudied, 
despite their importance in viral infections. They are grouped into different categories 
depending on the purpose of the motif and these motifs are employed by several pathogenic 
viruses to exploit the host cell pathways that can promote the progression of the viral life cycle 
[62-64].  
About one-third of the 3’-carboxyl terminus of hCoVs genomes encode for structural proteins 
as well as additional, so-called accessory proteins [65]. While the four structural proteins, spike 
(S), membrane (M), nucleocapsid (N), and envelope (E), are important for the assembly of a 
structurally complete virus, the accessory proteins are generally not essential for viral 
replication in vitro [65-68]. While each structural protein has its respective function(s), the E 
protein is the most enigmatic of them all and is also involved in very important aspects of the 
coronaviral life cycle. Its involvement in viral assembly is evident by its requirement in the 
formation of the viral envelope and virus-like particles, while the transmembrane domain 
(TMD) of E is necessary for the release of viral particles [69, 70]. Of particular relevance to 
this paper, and the current COVID-19 pandemic, however, is the function of E in the 
pathogenesis of hCoV infections. Data on the role of E exists predominantly for the prototypic 
SARS-CoV, which has been studied the most extensively, with some studies for MERS-CoV 
E. 
 
E protein: a contributor to hCoV pathogenesis 
Effective management and patient care of COVID-19 dictates that we have a better 
understanding of the disease initiation and progression, or pathogenesis. In the case of virulent 
viruses, it stands to reason that the natural progression of the viral life cycle would adversely 
affect the host. These adverse effects inherently give rise to symptoms and, ultimately, manifest 
clinically. Two documented functions of the hCoV E protein contribute to the pathogenesis of 
severe hCoV infections. 
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The PDZ-binding motif (PBM) 
All CoV E proteins share the same general architecture; a short, hydrophilic amino (N)-
terminus, approximately 8-12 residues in length, a subsequent 21-29 residue long hydrophobic 
region which typically contains two to four cysteine residues, followed by the hydrophilic C-
terminus, which accounts for the largest portion of the protein, 39-76 residues in length [65]. 
The last four residues of the C-terminus consists of a motif that allows binding to the 
postsynaptic density protein 95 (PSD95)/Drosophila disc large tumour suppressor 
(Dlg1)/zonula occludens-1 protein (zo-1) (PDZ) domain; a domain found in all eukaryotic host 
cells that functions as a protein-protein recognition sequence to drive host PPIs of significance 
to viruses [71]. These PDZ domains are found in a multitude of eukaryotic proteins and bind 
to a specific peptide sequence usually found at the end of the target protein C-terminus [72, 
73]. Some viruses, including SARS-CoV, encode proteins with a PDZ-binding motif (PBM) 
that enables them to exploit the PDZ domains of these host proteins to their advantage [74, 75]. 
This strategy is employed by viruses to modulate various cellular processes including cell-cell 
junctions, cellular polarity, and signal transduction pathways for the purpose of viral replication, 
dissemination, and pathogenesis [71]. The terminal portion of the SARS-CoV E protein C-
terminus contains a PBM that contributes to its viral pathogenesis and is known to interact with 
five host proteins [76]. It is classified as a type II PBM, characterised by the consensus 
sequence X-φ-X-φCOOH, where X represents any amino acid and φ is a hydrophobic residue, 
usually V, I or L [77]. 
The role of SARS-CoV E in the immune-mediated pathology of severe SARS infections is 
very well demonstrated by its interaction with the host cell protein, syntenin [78]. Mice infected 
with recombinant SARS-CoV (rSARS-CoV), containing a fully functional E protein, exhibited 
lung pathology characterised by severe oedema, areas of profuse haemorrhage, and cellular 
infiltrates. Further analysis showed that the PBM of SARS-CoV E interacted with the PDZ 
domain of syntenin and triggered an overexpression of pro-inflammatory cytokines that was 
mediated by the p38 mitogen-activated protein kinase (MAPK) pathway. Expression of pro-
inflammatory cytokines IL-1 and IL-6 as well as the acute phase protein serum amyloid A 
was notably increased. This resulted in an exacerbated the immune response towards the 
infection and the characteristic tissue damage and oedema ensued. The infection culminated in 
ARDS, consistent with severe cases of SARS-CoV infection. Mice infected with rSARS-CoV 
succumbed to the infection, while all mice infected with rSARS-CoV lacking E (E) survived 
[78]. Moreover, the authors reported an 80% increase in the survival rate of mice infected with 
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rSARS-CoV when treated with a p38 MAPK inhibitor. This, notably, demonstrates a clear 
relationship between the pathogenesis and clinical manifestation of SARS-CoV infections, as 
a direct consequence of the E protein. It also shows that the mortality rate of infected cases can 
be markedly reduced by limiting the aberrant immune response with a p38 MAPK inhibitor. 
So far, the novelty of SARS-CoV-2 has prohibited its complete characterisation which makes 
it challenging to confirm whether the functions of its viral proteins do, in fact, coincide with 
those already established for other hCoVs, like SARS-CoV. Despite its novelty, SARS-CoV-2 
shows a remarkable similarity to SARS-CoV in both clinical and genetic features, making it 
easier to use our existing knowledge of SARS-CoV to understand SARS-CoV-2 better. 
Previous reports have remarked that the overall sequence similarity of the E protein among 
hCoVs is poor [79, 80]. Still, comparing the E proteins of the pathogenic hCoVs, SARS-CoV, 
MERS-CoV, and SARS-CoV-2, shows a very high sequence similarity between SARS-CoV E 
and SARS-CoV-2 E, confirmed by only one other report and supporting the observed clinical 
similarity between the two hCoVs [81]. This similarity, however, is not shared with the MERS-
CoV E protein. 
A sequence comparison of the virulent hCoV E protein sequences demonstrates that important 
features such as the topological domains, conserved residues, and the PBM also remain largely 
intact across these hCoVs (Figure 1). The secondary structure of SARS-CoV E shows that it 
contains one TMD after a short N-terminus and, based on the similarity between SARS-CoV 
E and SARS-CoV-2 E having only a four amino acid difference, SARS-CoV-2 E follows the 
same architecture; one TMD that is most likely in the same location and consists of the same 
residues (Figure 1). Certain key residues are also conserved, particularly the cysteine residues 
at positions 40, 43, and 43 (C40, C43, C44), and a proline residue at position 54 (P54) (Figure 
1). Cysteine residues adjacent to the TMD of integral membrane proteins, like E, serve as 
targets for palmitoylation [82]. In different CoV E proteins, palmitoylated cysteine residues are 
important for viral assembly, protein-membrane interaction, and stabilization of the E protein 
[79, 83]. The importance of residues C40, C43, and C44 is, thus, highlighted by their 
conservation and proximity to the TMD. A chimeric SARS-CoV E protein showed the 
importance of P54 in the localisation of E to the Golgi complex as a chimeric E protein with a 
mutated P54 residue localized to the plasma membrane instead [84]. The conservation of 
residues C40, C43, C44, and P54 suggest that they might serve similar purposes in SARS-
CoV-2 than what they do in SARS-CoV. 
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The PBM of each hCoV, except MERS-CoV, also consists of at least two definitive 
hydrophobic residues (V, I, or L), consistent with the consensus sequence for a type II PBM 
(Figure 1) [77]. Only one of the four PBM residues in the PBM of MERS-CoV E is 
hydrophobic and another (tryptophan) is slightly more hydrophilic than hydrophobic, based on 
the Kyte and Doolittle [85] hydropathy table. However, the scarcity of information on hCoV E 
proteins other than SARS-CoV, makes it difficult to determine the exact reason for this. 
Nevertheless, the PBMs of SARS-CoV and SARS-CoV-2 are remarkably identical and, given 
the role of E in SARS-CoV pathogenesis, it supports the similarity in clinical presentation and 
severity of these two hCoV infections. It also suggests that the SARS-CoV-2 E PBM might 
interact with syntenin in manner similar to SARS-CoV E. Accordingly, this would allow for 
treatment strategies and patient care to adopt a more focussed approach as the existing data on 
the SARS-CoV E PBM and its role in SARS pathogenesis would be most beneficial in 
mitigating the immunopathology often seen in severe COVID-19 cases. Understandably, this 
sequence similarity merely suggests the existence of a relationship between the similarity of 
the SARS-CoV and SARS-CoV-2 E protein PBMs and the clinical presentations of these hCoV 
infections. Although it certainly is noteworthy, experimental evidence is required to 
corroborate whether this relationship is merely incidental, or whether it could potentially allude 
to the clinical manifestation or severity of a particular hCoV infection and whether it might be 
of therapeutic value in COVID-19 patients.  
The SARS-CoV E PBM further contributes to viral pathogenesis by its interaction with the 
PDZ domain of the protein associated with Caenorhabditis elegans lin-7 protein 1 (PALS1) 
[74]. The binding of SARS-CoV E to PALS1, a protein normally associated with tight junctions, 
redistributed it from the tight junctions of the lung epithelium to the ER-Golgi intermediate 
compartment (ERGIC) where E assembles. The authors proposed that the redistribution of 
PALS1 can progressively disrupt tight junctions and contribute to the desquamation of the 
alveolar wall, creating a breach in the epithelial barrier. This would allow virions to infiltrate 
the underlying tissues and reach the systemic circulation, disseminating to other organs. 
Although the study only managed to demonstrate the E-mediated redistribution of PALS1 in 
vitro, the clinical importance of this interaction is consistent with histopathological 
observations made in lung biopsies obtained from SARS-CoV-infected patients and 
cynomolgus macaques. The biopsies consistently demonstrated that severe DAD to the lung 
was accompanied by a massive infiltration of monocytes and macrophages in the alveolar space, 
a thickened epithelial wall, fused alveolar septa, and haemorrhagic septa with necrotic lesions 
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[19, 86, 87]. Further corroboration comes from studies that show massive recruitment of 
leukocytes to the site of infection through chemokines and cytokines produced by human 
airway epithelia, strongly implicating inflammation in the contribution of DAD [35, 88, 89]. 
Granted, although this interaction has only been demonstrated in SARS-CoV, it should not 
diminish the possibility of it occurring in a similar fashion in other virulent hCoV infections 
such as SARS-CoV-2. It is likely that the PBM of SARS-CoV-2 E can also interact with PALS1 
in an analogous manner and cause dissemination of the virus. In fact, the presence of a PBM 
at the C-terminus of each virulent hCoV indicates that they might all be capable of interacting 
with host proteins, such as syntenin and PALS1, similar to SARS-CoV. Experimental evidence 
is, of course, warranted to provide a solid scientific basis, but it would also provide much need 
valuable insight into why hCoVs clinically manifest in different severities.  
Viroporin and the inflammasome 
The hydrophobic TMD of the E protein is an important component necessary for the assembly 
of a multimeric structure known as a viroporin; low-molecular-weight proteins that typically 
contain an amphipathic -helix and are encoded by many animal viruses. Viroporins 
oligomerise and can channel various ions, altering the permeability properties of membranes 
within the host cell. Upon oligomerisation, viroporins form a hydrophilic pore that permits the 
transport of ions across the membrane as the hydrophilic residues face the interior of the pore 
and the hydrophobic residues face outward towards the phospholipid bilayer [90, 91]. The 
SARS-CoV E protein viroporin possesses ion-channel (IC) activity and can transport various 
ions (Na+, K+, Cl-, and Ca2+) [92, 93]. The importance of this IC property is evident in its 
contribution to the pathogenesis observed in a SARS infection. 
The (NOD)-like receptor protein 3 (NLRP3) inflammasome is a multimeric molecular platform 
that can be activated by several factors, including increased levels of intracellular Ca2+, and 
contributes to the inflammatory response by stimulating IL-1 production [94, 95]. The IC 
activity of the SARS-CoV E protein has been linked to activation of the inflammasome and 
disease severity [96]. Mice infected with IC-proficient rSARS-CoV E developed pulmonary 
oedema, lung damage, and succumbed to the infection due to significantly increased levels of 
inflammatory cytokines IL-1, IL-6, and TNF-. Conversely, mice infected with IC-deficient 
rSARS-CoV E exhibit reduced levels of inflammasome-activated IL-1, and mice recovered 
from the infection. The IC activity of SARS-CoV E, therefore, directly correlates with 
inflammasome activation and an ensuing inflammatory response that causes lung damage. The 
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inflammatory pathology was attributed to a Ca2+ imbalance that activated the NLRP3 
inflammasome and induced the production of IL-1 [92]. Only two other hCoV E proteins have 
been shown to possess IC activity: MERS-CoV and hCoV-229E [97, 98]. However, since no 
experimental evidence exists to link the IC property of either E protein to NLRP3 
inflammasome activation, it can only be hypothesised as to whether these hCoVs are equally 
capable of inducing a pathologic immune response as SARS-CoV does.  
Several other pathogenic viruses also possess viroporin proteins capable of activating the 
NLRP3 inflammasome; the small hydrophobic (SH) protein of respiratory syncytial virus, 
influenza virus M2 protein, encephalomyocarditis virus 2B protein, rhinovirus 2B protein, and 
the hepatitis C virus (HCV) p7 protein [91]. It is also worth mentioning that a number of 
viroporin inhibitors have been researched in an effort to inhibit the IC properties of the 
picornavirus, HCV, SARS-CoV, HIV-1, and influenza A virus. Most inhibitors, however, have 
exhibited some challenges, including mere moderate inhibition, the formation of resistant 
variants of viruses, and cytotoxic concentrations, preventing the clinical implementation of 
such inhibitors [99]. Given the challenges faced with these inhibitors, perhaps it would be more 
prudent to divert the attention towards addressing the fundamental source of viroporins: the 
viral protein itself.  
 
Cytokines IL-1 and IL-6 in SARS and COVID-19 immunopathology 
The presence of IL-1 in the pathogenesis and immunopathology of SARS has been well-
demonstrated. Interleukin-1 is a potent inflammatory cytokine – the result of a series of 
cellular signals and stimuli, involving the nuclear factor kappa B (NF-B) pathway and the 
NLRP3 inflammasome [95]. A variety of stimuli is capable of inducing IL-1 production, 
including products of infectious agents, ionic imbalances inside the cell, exogenous particulates, 
and molecules associated with cellular damage [95]. Once released into circulation, IL-1 can 
cause inflammation and perpetuate the inflammatory response by inducing IL-6 production 
[100-102]. Mice deficient in IL-1 displayed no levels of circulating IL-6 in response to 
turpentine [103]. Interleukin-1 can also modulate the production of IL-6 through STAT3 and 
NF-κB-dependent signalling pathways and involves acute phase proteins produced by the liver 
[104]. This demonstrates that the NF-κB pathway is quite involved in the production of 
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inflammatory cytokines and that targeting this pathway could be of therapeutic benefit at 
multiple levels: IL-1 production, IL-6 production, and IL-1-induced IL-6 production. 
Moreover, mice infected with IC-deficient rSARS-CoV E exhibited reduced levels of 
inflammasome-activated IL-1 in their lungs [96]. This reduction in IL-1 was accompanied 
by reduced levels of TNF and IL-6, demonstrating the importance of the E protein in the 
induction of an aberrant inflammatory response in SARS-CoV mice that contributes to the 
development of a cytokine storm, and ultimately culminates in ARDS. 
 
Discussion and Conclusion 
Despite the importance of the hCoV E protein, it is still poorly characterised and quite 
understudied. And although much progress has been made in hCoV research, the novelty of 
SARS-CoV-2 clearly leaves much still to be answered. The sequence similarity between the E 
proteins of SARS-CoV and SARS-CoV-2 strongly suggest the likelihood that these two 
proteins serve nearly identical purposes in the pathogenesis of COVID-19. Admittedly, a great 
divergence exists in the amino acid sequences of the E protein between the different CoV 
groups and, to an extent, within some of the groups. But the overall features and functions of 
the CoV E still remain largely intact [65]. The importance of the E protein is evident by its 
involvement in the pathogenesis of SARS-CoV, and possibly SARS-CoV-2, making it an ideal 
therapeutic candidate. Already, a p38 MAPK inhibitor has shown promise in mice by 
alleviating the inflammation-induced symptoms brought on by the SARS-CoV E protein. 
Given the involvement of hCoV E in various aspects of the coronaviral life cycle, targeting E 
could hold the potential to stopping the spread of infection while simultaneously alleviating 
the symptoms and managing complications such as ARDS in severe SARS-CoV infections. 
Coronaviral research would certainly benefit from investigating the therapeutic potential of a 
p38 MAPK inhibitor in a SARS-CoV-2 infection of mice. The gravity of the COVID-19 
pandemic warrants more research into hCoVs and how such outbreaks can be addressed, now 
more than ever. 
Currently, vaccine and antiviral research are being done at a near-unprecedented rate, but while 
an effective countermeasure might only be available in as soon as twelve months, the hCoV 
pandemic continues to have a significant impact on people all over the world. The SARS-CoV 
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E protein is paramount to the pathogenesis of the SARS disease as rSARS-CoV-E viruses 
show no excessive inflammatory response and spare mice from immune-mediated lung damage. 
Our paper proposes the use of immunomodulatory or anti-inflammatory drugs that specifically 
target the already well-characterised inflammatory pathways activated by SARS-CoV E. Given 
the importance of IL-1 and IL-6 in the development of ARDS, drugs that expressly target IL-
1 and IL-6 could lead to more favourable patient outcomes and reduce the rising mortality 
rate of COVID-19 while vaccine and antiviral research continue. 
Amid the global rise in the mortality rate of COVID-19, effective management of inflammation 
and the cytokine storm, the crucial features of ARDS, should be of considerable priority. The 
use of the IL-6 receptor blocker, tocilizumab effectively reversed the cytokine storm in acute 
lymphocytic anaemia [105, 106]. Tocilizumab has, accordingly, been suggested for use in the 
treatment of severe COVID-19, where Xu, et al. [107] has reported some promise in severe 
COVID-19 patients [108, 109]. Already, blocking IL-1 activity in a broad array of 
inflammatory diseases has shown reduced disease severity and a reduction in the burden of 
disease [110]. Inhibitors of IL-1 typically include the IL‑1 receptor antagonist (Anakinra), the 
soluble decoy receptor (Rilonacept), and the anti‑IL‑1β monoclonal antibody (Canakinumab) 
[111]. The efficacy of rilonacept and canakinumab has even garnered approval by 
pharmaceutical companies, making such IL-1-directed therapies deserving of study as potential 
treatments to manage severe cases of COVID-19 [112].  
The cellular pathways that lead to IL-1 and IL-6 production are well-characterised and could 
also serve as valuable therapeutic targets. A p38 MAPK pathway inhibitor led to an 80% 
survival rate of rSARS-CoV-infected mice, showing both the relevance of this pathway in 
SARS infections and the potential of this inhibitor in successfully managing severe cases of 
COVID-19 [78]. Furthermore, inhibition of the Janus kinase/signal transducer and activator of 
transcription (JAK-STAT) pathway by ruxolitinib is effective in the treatment of 
haemophagocytic lymphohistiocytosis, a hyperinflammatory condition also characterised by a 
cytokine storm [113]. The JAK-STAT pathway is a common signal transduction pathway 
involved in the expression of many other cytokines also responsible for the immune-mediated 
damage of ARDS typical of severe SARS cases. Accordingly, this pathway can also be a target 
for blocking multiple cytokines simultaneously. 
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The importance of the hCoV E protein and its associated pathways is also demonstrated in the 
potential of a SARS-CoV-2 vaccine that lacks an E protein. Without the E protein to induce a 
cytokine storm, and subsequent complications like ARDS, undesired side-effects will be 
limited, while the vaccine still confers the necessary protection. Some studies have already 
demonstrated the potential of developing rSARS-CoV-E vaccines, or ones with a mutated E 
protein to limit pathogenesis while still conferring the needed protection against a viral 
challenge after vaccination [114-116]. Vaccines based on rSARS-CoV-ΔE remain their 
immunogenicity and efficacy, developing robust cellular and humoral immune responses and 
effective despite an impaired ability to replicate in the host. One study even showed that a 
rSARS-CoV-ΔE-based vaccine can protect both young and aged mice, with no clinical disease 
observed in mice of any ages [117]. The authors, however, cautioned prudence in the design 
of such vaccines, highlighting the need to possibly introduce additional mutations to enhance 
safety due to the recombinatory nature of CoVs [26, 65]. 
Admittedly, data on CoV E is sparse, but it should not reflect negatively on the importance of 
the protein in hCoV infections, especially not in the case of serious ones such as SARS-CoV-
2. On the contrary, the importance of the E protein should, instead, underpin the need for more 
research in an effort to limit any likelihood of a future outbreak, possibly a more severe one. If 
there is anything to learn from the SARS, MERS and COVID-19 outbreaks, it is that we do not 
know when they will happen nor what the nature of the outbreak will be. The more data we 
have on previous outbreaks, the better prepared we can be. 
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FIGURES and TABLES 
 
 
Figure 1: A sequence comparison of the envelope (E) protein amino acid sequences for the 
pathogenic human coronaviruses (hCoVs). The comparison was constructed using Jalview 
software (v 2.11.1.0). Important sequence features transmembrane domain (TMD) (gray), 
conserved cysteine (blue) and proline (orange) residues, and the PDZ-binding motif (PBM) 
(red) are indicated. The E protein reference sequences for SARS-CoV (Q19QW7), MERS-CoV 
(R9UQN1), and SARS-CoV-2 (YP_009724392.1) were obtained from the NCBI database. 
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